Michael Michael

Summary

Affiliation: University of Melbourne
Country: Australia

Publications

  1. pmc Incorporating PET information in radiation therapy planning
    M MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Biomed Imaging Interv J 3:e4. 2007
  2. ncbi request reprint Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure
    M P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 46:63-9. 2000
  3. ncbi request reprint Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer
    M MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Australas Radiol 51:386-93. 2007
  4. ncbi request reprint Impact of PET on radiation therapy planning in lung cancer
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Radiol Clin North Am 45:627-38, v. 2007
  5. ncbi request reprint Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Lung Cancer 49:95-108. 2005
  6. pmc Overview of early response assessment in lymphoma with FDG-PET
    Michael P MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Cancer Imaging 7:10-8. 2007
  7. ncbi request reprint PET scanning in lung cancer: current status and future directions
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, St Andrew s Place, East Melbourne, Vic, Australia
    Semin Surg Oncol 21:149-55. 2003
  8. ncbi request reprint FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden
    Michael R MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Acta Oncol 42:48-54. 2003
  9. ncbi request reprint Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    J Clin Oncol 21:1285-92. 2003
  10. ncbi request reprint High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy
    M P MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 50:287-93. 2001

Detail Information

Publications54

  1. pmc Incorporating PET information in radiation therapy planning
    M MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Biomed Imaging Interv J 3:e4. 2007
    ..The best means of incorporating PET information into radiotherapy planning is uncertain, and considerable effort is being expended in this area of research...
  2. ncbi request reprint Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure
    M P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 46:63-9. 2000
    ....
  3. ncbi request reprint Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer
    M MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Australas Radiol 51:386-93. 2007
    ..Use of coregistered PET/CT images significantly altered treatment plans in a majority of cases. This method could be used in routine practice at centres without access to a combined PET/CT scanner ...
  4. ncbi request reprint Impact of PET on radiation therapy planning in lung cancer
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Radiol Clin North Am 45:627-38, v. 2007
    ..PET will allow for more accurately targeted dose escalation studies in the future and could potentially lead to better long-term survival...
  5. ncbi request reprint Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Lung Cancer 49:95-108. 2005
    ..PET-response, survival and patterns of failure data are presented with long-term follow-up...
  6. pmc Overview of early response assessment in lymphoma with FDG-PET
    Michael P MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Cancer Imaging 7:10-8. 2007
    ....
  7. ncbi request reprint PET scanning in lung cancer: current status and future directions
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, St Andrew s Place, East Melbourne, Vic, Australia
    Semin Surg Oncol 21:149-55. 2003
    ..PET has rapidly become an indispensable part of the evaluation of patients with potentially curable lung cancer; however, more work is required to define its role...
  8. ncbi request reprint FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden
    Michael R MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Acta Oncol 42:48-54. 2003
    ..027) but not pre-PET stage, weight loss or metastasis site correlated with survival. PET-detected metastatic tumor burden appeared to influence survival and should be evaluated as a prognostic factor in NSCLC...
  9. ncbi request reprint Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    J Clin Oncol 21:1285-92. 2003
    ..PET is known to provide a more accurate estimate of true extent of disease than CT when used to stage non-small-cell lung cancer (NSCLC)...
  10. ncbi request reprint High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy
    M P MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 50:287-93. 2001
    ..We tested the hypothesis that positron emission tomography (PET) using 18-F fluorodeoxyglucose (FDG) would detect more unsuspected metastases in apparent Stage III disease than in Stages I-II...
  11. ncbi request reprint Imaging with F-18 FDG PET is superior to Tl-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy
    M P MacManus
    Division of Radiation Oncology and Department of Diagnostic Imaging, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Australas Radiol 45:483-90. 2001
    ....
  12. ncbi request reprint Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 52:351-61. 2002
    ..We hypothesized that early cancer death rates would be lower in patients receiving RRT after PET staging compared with conventionally staged patients...
  13. ncbi request reprint Management of localized low-grade follicular lymphomas
    M P MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, St Andrew s Place, Melbourne, Victoria 3002, Australia
    Australas Radiol 45:326-34. 2001
    ..This report reviews the literature on the management of localized low-grade lymphoma and discusses the rationale for the TROG/ALLG study, which began recruitment in early 2000...
  14. ncbi request reprint F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment
    M P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, A Beckett Street, Melbourne, Victoria 3000, Australia
    Cancer 92:886-95. 2001
    ..The authors investigated FDG-PET staging in radical RT candidates with unresectable NSCLC...
  15. ncbi request reprint Exacerbation, then clearance, of mutation-proven Darier's disease of the skin after radiotherapy for bronchial carcinoma: a case of radiation-induced epidermal differentiation?
    M P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, VIC 8006, Australia
    Radiat Res 156:724-30. 2001
    ..Oncologists treating malignant disease in patients with DD should anticipate temporary deterioration in DD-involved irradiated skin. Radiation therapy has therapeutic potential in severe DD...
  16. pmc Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity
    Charles H C Pilgrim
    Division of Cancer Surgery, Peter MacCallum Cancer Centre, Department of Surgery, University of Melbourne, St Vincent s Hospital, Melbourne, Australia
    HPB (Oxford) 14:333-40. 2012
    ..The aim of the present study was to draw correlations between clinical features, treatment with chemotherapy and injury phenotypes and assess the impact of each upon perioperative morbidity...
  17. ncbi request reprint Long-term survival following chemoradiation for inoperable non-small cell lung cancer
    Nikki M Plumridge
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Med J Aust 189:557-9. 2008
    ..To measure long-term survival following combined chemotherapy and radiotherapy for inoperable non-small cell lung cancer...
  18. doi request reprint Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer
    Marie Pierre Campeau
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 74:1371-5. 2009
    ..The effect of CRT on local control in Stage I NSCLC is less well documented. We retrospectively reviewed local control and survival following CRT or RT for inoperable Stage I NSCLC patients...
  19. ncbi request reprint The developing clinical problem of chemotherapy-induced hepatic injury
    Charles H C Pilgrim
    Division of Cancer Surgery, Peter MacCallum Cancer, Melbourne, Australia
    ANZ J Surg 82:23-9. 2012
    ..The need for methods to identify patients at risk of CIHI and to recognize established CIHI prior to surgery will be emphasized...
  20. ncbi request reprint Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience
    Robert Blum
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Vic, Australia
    Am J Clin Oncol 27:164-71. 2004
    ..PET-CR conferred longer median time to progression (13.7 months) than no CR (9.7 months). FDG-PET for SCLC was often discordant with conventional assessment and frequently influenced management...
  21. ncbi request reprint FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer
    Cuong P Duong
    Division of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Eur J Nucl Med Mol Imaging 33:770-8. 2006
    ..The purpose of this study was to evaluate the impact of FDG-PET following chemoradiotherapy (CRT) on treatment planning and survival in patients with oesophageal cancer (OC)...
  22. ncbi request reprint Impact of advancing age on treatment and outcomes in anal cancer
    Marcus Foo
    Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Acta Oncol 53:909-16. 2014
    ..The authors compared tolerability and outcomes across the age groups following CRT for SCCA...
  23. doi request reprint A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients
    Peter Gibbs
    Department of Medical Oncology and Haematology, Royal Melbourne Hospital, Melbourne, Australia
    Chemotherapy 55:49-59. 2009
    ..This study was designed as a first-in-man investigation of the safety and pharmacokinetics of irinotecan when administered within the HA-Irinotecan formulation...
  24. doi request reprint Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Grou
    Trevor Leong
    Division of Radiation Oncology, Department of Radiation Therapy Services, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 79:690-5. 2011
    ..We conducted a prospective, multicenter study to evaluate an alternative chemoradiation regimen that combines more current systemic treatment with modern techniques of radiotherapy delivery...
  25. ncbi request reprint Locally advanced and metastatic gastric cancer: current management and new treatment developments
    Kathryn Field
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Drugs 68:299-317. 2008
    ..Overall, there remains optimism that further incremental gains will be achieved with future studies combining chemotherapy, radiotherapy and targeted therapies, both in the adjuvant and metastatic disease settings...
  26. pmc mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury
    Charles H C Pilgrim
    Division of Cancer Surgery, The Alfred Hospital Department of Pathology, The Alfred Hospital, Melbourne, Victoria, Australia
    HPB (Oxford) 13:811-6. 2011
    ..It may be possible to predict the risk of developing CIHI by analysis of genes involved in the metabolism of chemotherapeutics, previously established as associated with other forms of toxicity...
  27. ncbi request reprint Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experience
    Michael Ng
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Thorac Oncol 2:506-13. 2007
    ..We have reviewed the experience at Peter MacCallum Cancer Centre to determine the tolerability of these treatments in routine practice and to determine their effects on survival...
  28. ncbi request reprint Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer
    Kenneth Khamly
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria 8006, Australia
    Expert Opin Investig Drugs 14:607-28. 2005
    ..This paper reviews these and other advances in the care of patients with advanced colorectal cancer and discusses a number of agents that are currently under development...
  29. doi request reprint Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
    Michael Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, 3002, Australia
    Invest New Drugs 27:253-61. 2009
    ..The safety and tolerability of vandetanib plus mFOLFOX6 was investigated in patients with advanced colorectal cancer (CRC)...
  30. doi request reprint Twenty-five-year experience with radical chemoradiation for anal cancer
    Jonathan M Tomaszewski
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 83:552-8. 2012
    ..To evaluate the prognostic factors, patterns of failure, and late toxicity in patients treated with chemoradiation (CRT) for anal cancer...
  31. ncbi request reprint Recent developments in the systemic therapy of advanced gastroesophageal malignancies
    Kenneth Khamly
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria 8006, Australia
    Expert Opin Investig Drugs 15:131-53. 2006
    ..This article reviews the current clinical data regarding systemic therapy for patients with advanced upper gastrointestinal malignancies...
  32. ncbi request reprint Part I: Liver function in oncology: biochemistry and beyond
    Kathryn M Field
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, Vic, Australia
    Lancet Oncol 9:1092-101. 2008
    ....
  33. ncbi request reprint Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome
    Ross R Jennens
    Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Urol Oncol 22:193-6. 2004
    ..While vascular endothelial growth factor (VEGF) inhibitors have been shown to produce a modest response in sporadic metastatic RCC, further studies utilizing VEGF inhibitors in patients with VHL syndrome and RCC warrants exploration...
  34. doi request reprint Targeted therapies for gastric cancer: current status
    Jaclyn Yoong
    Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Drugs 71:1367-84. 2011
    ....
  35. ncbi request reprint Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count
    Michael Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, 8006, Australia
    Clin Colorectal Cancer 6:297-304. 2006
    ..The aim of this study was to identify prognostic indicators of survival and response in a homogeneous population of chemotherapy-naive patients treated with oxaliplatin as part of 3 successive trials...
  36. ncbi request reprint 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
    Daniel Hubble
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew s Place, East Melbourne, VIC 3002, Australia
    Eur J Nucl Med Mol Imaging 37:1869-75. 2010
    ....
  37. ncbi request reprint A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy
    Sherene Loi
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Chemother Pharmacol 54:407-14. 2004
    ..We sought to determine the effect of a 3-h infusion of 20 ml/m2 (equivalent to 175 mg/m2 paclitaxel) CrEL on myelosuppression following carboplatin chemotherapy, and the effect of CrEL on carboplatin pharmacokinetics...
  38. ncbi request reprint Adjuvant therapy in gastric cancer
    Lionel Lim
    Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    J Clin Oncol 23:6220-32. 2005
    ..Issues such as the identification of patients who are more likely to benefit from adjuvant therapy are also addressed. Further clinical trials are needed to move towards better consensus and standardization of care...
  39. doi request reprint The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum
    Jennifer A Westwood
    Cancer Immunology Research Program, Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Victoria 3002, Australia
    J Immunother 32:292-301. 2009
    ....
  40. ncbi request reprint Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination
    Michael Michael
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
    J Clin Oncol 24:4228-35. 2006
    ....
  41. ncbi request reprint Understanding how cancer patients actualise, relinquish, and reject advance care planning: implications for practice
    Natasha Michael
    Department of Pain and Palliative Care, Peter MacCallum Cancer Centre, Peter Mac, Locked Bag 1, A Beckett Street, Victoria, Vic, 8006, Australia
    Support Care Cancer 21:2195-205. 2013
    ..This study examines how Australian cancer patients consider ACP. Responses will inform the development of an Australian Cancer Centre's ACP programme...
  42. ncbi request reprint Part II: Liver function in oncology: towards safer chemotherapy use
    Kathryn M Field
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Lancet Oncol 9:1181-90. 2008
    ..Furthermore, we review other assessments of liver metabolic and excretory function, particularly in the setting of chemotherapy drug handling. We discuss the potential use of these metabolic probes in practice...
  43. ncbi request reprint Implications of dose rounding of chemotherapy to the nearest vial size
    Michael Joseph Dooley
    Pharmacy Department, Peter MacCallum Cancer Centre, St Andrew s Place, 3002 East Melbourne, Australia
    Support Care Cancer 12:653-6. 2004
    ..The objective here was to explore the magnitude of the effect of dose rounding to the nearest whole vial strength for some newly marketed expensive cytotoxic chemotherapy agents...
  44. ncbi request reprint A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer
    Michael Jefford
    Centre for Developmental Cancer Therapeutics, Melbourne, Victoria, Australia
    Invest New Drugs 22:185-92. 2004
    ..We conducted a dose escalation study combining cisplatin, irinotecan, and capecitabine (CIC), aiming to establish the maximum tolerated doses (MTD), side effect profile, and dose-limiting toxicity (DLT) of this novel regimen...
  45. ncbi request reprint Drug metabolism by tumours: its nature, relevance and therapeutic implications
    Michael Michael
    Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology, Locked Bag 1, A Beckett Street, Victoria, 8006, Australia
    Expert Opin Drug Metab Toxicol 3:783-803. 2007
    ..Only then can efforts be concentrated in the design of better prodrugs or combination therapy to optimise individual therapy...
  46. pmc Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
    Linda Mileshkin
    Division of Cancer Medicine, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC 3002, Australia
    Chemother Res Pract 2012:838509. 2012
    ..In this paper, we review these issues, by discussing these two examples in detail and suggest some actions for addressing potential barriers...
  47. ncbi request reprint CNS listeriosis confused with leptomeningeal carcinomatosis in a patient with a malignant insulinoma
    Linda Mileshkin
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Am J Clin Oncol 25:576-9. 2002
    ..The clinical and radiologic features of this illustrative case are described. Listeriosis is an important treatable differential diagnosis in patients with malignancy presenting with neurologic signs...
  48. doi request reprint Role of xenobiotic metabolic enzymes in cancer epidemiology
    Madhu S Singh
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
    Methods Mol Biol 472:243-64. 2009
    ..The data may have relevance in one population but not for another for a specific malignancy and at times may be conflicting. We believe that with mature data in the future it may be possible to stratify patients by risk...
  49. ncbi request reprint Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy
    Stephen Clarke
    Department of Medical Oncology, Royal Prince Alfred Hospital Sydney Cancer Centre, Sydney, Australia
    Clin Colorectal Cancer 6:578-82. 2007
    ..This analysis assesses the efficacy and safety of a modified FOLFOX (oxaliplatin/leucovorin [LV]/5-fluorouracil [5-FU]) regimen given with a low dose of LV...
  50. ncbi request reprint Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer
    Fiona H Blackhall
    Department of Medical Oncology, University Health Network Princess Margaret Hospital, University of Toronto, Toronto, Ontario, M5G 2M5 Canada
    Clin Cancer Res 9:2241-7. 2003
    ..This study was designed to examine the expression and importance of Kit, PKB/Akt, and MAPK relative to standard clinical prognostic factors in SCLC...
  51. ncbi request reprint Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity
    Paul L Mitchell
    Austin Hospital, Heidelberg, Melbourne, Australia E mail
    Clin Colorectal Cancer 6:146-51. 2006
    ..Sensory neurotoxicity is dose limiting for oxaliplatin, an effective drug in the treatment of colorectal cancer (CRC) and other malignancies. This study assessed the impact of gabapentin on oxaliplatin dose intensity and neurotoxicity...
  52. ncbi request reprint Benign childhood focal epilepsies: assessment of established and newly recognized syndromes
    Chrysostomos P Panayiotopoulos
    Department of Clinical Neurophysiology and Epilepsies, St Thomas Hospital, London, UK
    Brain 131:2264-86. 2008
    ..Taking all these into account, benign childhood focal seizures and related epileptic syndromes would need proper multi-disciplinary re-assessment in an evidence-based manner...
  53. ncbi request reprint A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy
    Ian D Davis
    Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    Clin Cancer Res 11:1890-8. 2005
    ....